Company research / SPRO
Spero Therapeutics, Inc. (SPRO)
- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
For the year ended 2025-12-31, Spero Therapeutics, Inc. reported revenue of $66.80M. Revenue grew 39.2% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $47.00M.
Key ratios (year ended 2025-12-31)
9.5%
Operating margin
12.8%
Net margin
14.5%
Return on year-end equity
39.2%
Revenue growth (YoY)
Beyond the statements
Follow the company.
Explore new filings, reported insider transactions and company relationships.